Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2022-02-09 15:48:28 UTC |
---|
NP-MRD ID | NP0000077 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Pyroglutamic acid |
---|
Description | Pyroglutamic acid (5-oxoproline) is a cyclized derivative of L-glutamic acid. It is an uncommon amino acid derivative in which the free amino group of glutamic acid cyclizes to form a lactam. It is formed nonenzymatically from glutamate, glutamine, and gamma-glutamylated peptides, but it can also be produced by the action of gamma-glutamylcyclotransferase on an L-amino acid. Elevated blood levels may be associated with problems of glutamine or glutathione metabolism. This compound is found in substantial amounts in brain tissue and other tissues in bound form, especially skin. It is also present in plant tissues. It is sold, over the counter, as a "smart drug" for improving blood circulation in the brain. Pyroglutamate in the urine is a biomarker for the consumption of cheese. When present in sufficiently high levels, pyroglutamic acid can act as an acidogen and a metabotoxin. An acidogen is an acidic compound that induces acidosis, which has multiple adverse effects on many organ systems. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of pyroglutamic acid are associated with at least five inborn errors of metabolism including 5-oxoprolinuria, 5-oxoprolinase deficiency, glutathione synthetase deficiency, hawkinsinuria, and propionic acidemia. Pyroglutamic acid is an organic acid. Abnormally high levels of organic acids in the blood (organic acidemia), urine (organic aciduria), the brain, and other tissues lead to general metabolic acidosis. Acidosis typically occurs when arterial pH falls below 7.35. In infants with acidosis the initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy). These can progress to heart, liver, and kidney abnormalities, seizures, coma, and possibly death. These are also the characteristic symptoms of the untreated IEMs mentioned above. Many affected children with organic acidemias experience intellectual disability or delayed development. In adults, acidosis or acidemia is characterized by headaches, confusion, feeling tired, tremors, sleepiness, and seizures. |
---|
Structure | InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(-)-2-Pyrrolidone-5-carboxylic acid | ChEBI | (S)-(-)-2-Pyrrolidone-5-carboxylic acid | ChEBI | (S)-Pyroglutamic acid | ChEBI | 5-Pyrrolidone-2-carboxylic acid | ChEBI | L-5-Pyrrolidone-2-carboxylic acid | ChEBI | L-Pyroglutamic acid | ChEBI | Pidolic acid | ChEBI | Pyroglutamate | ChEBI | 5-oxo-L-Proline | Kegg | (-)-2-Pyrrolidone-5-carboxylate | Generator | (S)-(-)-2-Pyrrolidone-5-carboxylate | Generator | (S)-Pyroglutamate | Generator | 5-Pyrrolidone-2-carboxylate | Generator | L-5-Pyrrolidone-2-carboxylate | Generator | L-Pyroglutamate | Generator | Pidolate | Generator | (-)-Pyroglutamate | HMDB | (-)-Pyroglutamic acid | HMDB | (5S)-2-Oxopyrrolidine-5-carboxylate | HMDB | (5S)-2-Oxopyrrolidine-5-carboxylic acid | HMDB | (S)-(-)-g-Butyrolactam-g-carboxylate | HMDB | (S)-(-)-g-Butyrolactam-g-carboxylic acid | HMDB | (S)-(-)-gamma-Butyrolactam-gamma-carboxylate | HMDB | (S)-(-)-gamma-Butyrolactam-gamma-carboxylic acid | HMDB | (S)-2-Pyrrolidone-5-carboxylate | HMDB | (S)-2-Pyrrolidone-5-carboxylic acid | HMDB | (S)-5-oxo-2-Pyrrolidinecarboxylate | HMDB | (S)-5-oxo-2-Pyrrolidinecarboxylic acid | HMDB | 2-L-Pyrrolidone-5-carboxylate | HMDB | 2-L-Pyrrolidone-5-carboxylic acid | HMDB | 2-Oxopyrrolidine-5(S)-carboxylate | HMDB | 2-Oxopyrrolidine-5(S)-carboxylic acid | HMDB | 2-Pyrrolidinone-5-carboxylate | HMDB | 2-Pyrrolidinone-5-carboxylic acid | HMDB | 5-Carboxy-2-pyrrolidinone | HMDB | 5-L-Oxoproline | HMDB | 5-Oxoproline | HMDB | 5-Pyrrolidinone-2-carboxylate | HMDB | 5-Pyrrolidinone-2-carboxylic acid | HMDB | Ajidew a 100 | HMDB | Glutimate | HMDB | Glutimic acid | HMDB | Glutiminate | HMDB | Glutiminic acid | HMDB | L-2-Pyrrolidone-5-carboxylate | HMDB | L-2-Pyrrolidone-5-carboxylic acid | HMDB | L-5-Carboxy-2-pyrrolidinone | HMDB | L-5-oxo-2-Pyrrolidinecarboxylate | HMDB | L-5-oxo-2-Pyrrolidinecarboxylic acid | HMDB | L-5-Oxoproline | HMDB | L-Glutamic acid g-lactam | HMDB | L-Glutimate | HMDB | L-Glutimic acid | HMDB | L-Glutiminate | HMDB | L-Glutiminic acid | HMDB | L-Pyrrolidinonecarboxylate | HMDB | L-Pyrrolidinonecarboxylic acid | HMDB | L-Pyrrolidonecarboxylate | HMDB | L-Pyrrolidonecarboxylic acid | HMDB | Oxoproline | HMDB | Oxopyrrolidinecarboxylate | HMDB | Oxopyrrolidinecarboxylic acid | HMDB | Pidolidone | HMDB | Pyrrolidinonecarboxylate | HMDB | Pyrrolidinonecarboxylic acid | HMDB | Pyrrolidone-5-carboxylate | HMDB | Pyrrolidone-5-carboxylic acid | HMDB | Pyrrolidonecarboxylic acid | HMDB | 5-Ketoproline | HMDB | Pidolate, magnesium | HMDB | 5-Oxopyrrolidine-2-carboxylic acid | HMDB | Magnesium pidolate | HMDB | 2-Pyrrolidone-5-carboxylic acid | HMDB | 5-Oxoprolinate | HMDB | PCA | HMDB |
|
---|
Chemical Formula | C5H7NO3 |
---|
Average Mass | 129.1140 Da |
---|
Monoisotopic Mass | 129.04259 Da |
---|
IUPAC Name | (2S)-5-oxopyrrolidine-2-carboxylic acid |
---|
Traditional Name | pyroglutamic acid |
---|
CAS Registry Number | 98-79-3 |
---|
SMILES | OC(=O)[C@@H]1CCC(=O)N1 |
---|
InChI Identifier | InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1 |
---|
InChI Key | ODHCTXKNWHHXJC-VKHMYHEASA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, simulated) | Ahselim | | | 2022-02-09 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Alpha amino acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Alpha-amino acid or derivatives
- Pyrroline carboxylic acid
- Pyrroline carboxylic acid or derivatives
- Pyrroline
- Cyclic carboximidic acid
- Lactim
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Azacycle
- Organoheterocyclic compound
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organic oxide
- Hydrocarbon derivative
- Carbonyl group
- Organic nitrogen compound
- Organonitrogen compound
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | |
---|
Predicted Properties | |
---|
General References | - Wevers RA, Engelke U, Heerschap A: High-resolution 1H-NMR spectroscopy of blood plasma for metabolic studies. Clin Chem. 1994 Jul;40(7 Pt 1):1245-50. [PubMed:8013094 ]
- Manning NJ, Davies NP, Olpin SE, Carpenter KH, Smith MF, Pollitt RJ, Duncan SL, Larsson A, Carlsson B: Prenatal diagnosis of glutathione synthase deficiency. Prenat Diagn. 1994 Jun;14(6):475-8. [PubMed:7937585 ]
- Caspers PJ, Lucassen GW, Carter EA, Bruining HA, Puppels GJ: In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. J Invest Dermatol. 2001 Mar;116(3):434-42. [PubMed:11231318 ]
- Hussain Z, Lannigan R, Stoakes L: A new approach for presumptive identification of clinically important streptococci. Zentralbl Bakteriol Mikrobiol Hyg A. 1984 Oct;258(1):74-9. [PubMed:6441390 ]
- Creer MH, Lau BW, Jones JD, Chan KM: Pyroglutamic acidemia in an adult patient. Clin Chem. 1989 Apr;35(4):684-6. [PubMed:2702756 ]
- Hammond JW, Potter M, Truscott R, Wilcken B: gamma-Glutamylglutamine identified in plasma and cerebrospinal fluid from hyperammonaemic patients. Clin Chim Acta. 1990 Dec 24;194(2-3):173-83. [PubMed:2093471 ]
- Uhlhaas S, Lange H: Striatal deficiency of L-pyroglutamic acid in Huntington's disease is accompanied by increased plasma levels. Brain Res. 1988 Aug 2;457(1):196-9. [PubMed:2971422 ]
- Croal BL, Glen AC, Kelly CJ, Logan RW: Transient 5-oxoprolinuria (pyroglutamic aciduria) with systemic acidosis in an adult receiving antibiotic therapy. Clin Chem. 1998 Feb;44(2):336-40. [PubMed:9474033 ]
- Winslow JW, Shih A, Bourell JH, Weiss G, Reed B, Stults JT, Goldsmith LT: Human seminal relaxin is a product of the same gene as human luteal relaxin. Endocrinology. 1992 May;130(5):2660-8. [PubMed:1572287 ]
- Erasmus E, Mienie LJ, de Vries WN, de Wet WJ, Carlsson B, Larsson A: Prenatal analysis in two suspected cases of glutathione synthetase deficiency. J Inherit Metab Dis. 1993;16(5):837-43. [PubMed:8295398 ]
- Sagaama A, Brandan SA, Ben Issa T, Issaoui N: Searching potential antiviral candidates for the treatment of the 2019 novel coronavirus based on DFT calculations and molecular docking. Heliyon. 2020 Aug 6;6(8):e04640. doi: 10.1016/j.heliyon.2020.e04640. eCollection 2020 Aug. [PubMed:32802981 ]
|
---|